Europe’s largest privately held biotech, BioNTech SE, is adding to its clinical-stage product pipeline through the acquisition of antibody assets and US infrastructure from San Diego, CA-based MabVax Therapeutics Holdings Inc., in an agreement announced on 9 May. The acquisition will include the antibody, MVT-5873, in Phase I in patients with pancreatic cancer, and preclinical antibodies.
The Strüngmann family-backed BioNTech has more than 1,000 employees in Mainz and other sites in Germany, and the infrastructure acquired...








